Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003001-94-SK (EUCTR)	06/11/2019	13/09/2019	Use of GLP-1 analogs in the treatment of multiple sclerosis	Use of GLP-1 analogs in the treatment of multiple sclerosis - MSGLP	Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurodegeneration, and manifested by insulin resistance in both peripheral tissues and the CNS. MedDRA version: 21.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere . Product Name: Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere	Lekárska fakulta UK Bratislava	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	Slovakia
2	NCT02988401 (ClinicalTrials.gov)	December 1, 2017	7/12/2016	Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis	Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: Insulin;Drug: Placebo (Sterile diluent)	Johns Hopkins University	United States Department of Defense	Completed	18 Years	70 Years	All	105	Phase 1/Phase 2	United States
3	NCT00001669 (ClinicalTrials.gov)	July 1997	3/11/1999	A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients	A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients	Multiple Sclerosis	Drug: rhIGF-1 (CEP-151)	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	15	Phase 2	United States